Trial Profile
The switching therapy with Ranibizumab for Exudative Age-related Macular Degeneration resistant to Aflibercept
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2014
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 07 Jan 2014 New trial record